|search over 1,000 Venture Capital related sites|
|1.||Cambridge Research BioVentures (100%):|
CAMBRIDGE RESEARCH BIOVENTURES Cambridge Research BioVentures (CRB) is a technology investment fund established to support the early development of promising biomedical and life sciences discoveries. Research Corporation Technologies (RCT) of Tucson, Arizona has made 8 million available to the fund,...
|2.||Abingworth - Portfolio Companies (84%):|
Portfolio Companies Abingworth Bioventures III Akubio (Cambridge, England) has developed a novel, highly sensitive detection technology that has potential applications in drug discovery and diagnostics (07/01) Alnylam Pharmaceuticals (Cambridge, Massachusetts) is developing novel RNA interference- (...
|3.||Abingworth - Portfolio Companies (75%):|
Portfolio Companies Abingworth Bioventures II Adiana (Redwood City, California) is developing devices for non-surgical, office-based gynaecological procedures. The company's lead product is a minimally invasive alternative to tubal ligation that is designed to provide permanent fallopian tube occlus...
|4.||Abingworth - Portfolio Companies (60%):|
Portfolio Companies Abingworth Bioventures IV Ablynx (Ghent, Belgium) is discovering and developing novel, proprietary antibody-like molecules called nanobodies. These nanobodies are being developed both as target validation tools and as therapeutics. The unique properties of nanobodies allow them t...
|5.||Abingworth - Portfolio Companies (60%):|
Portfolio Companies Abingworth Bioventures IIa ABVIIa is an annex fund to ABVII Abingworth Bioventures IV Abingworth Bioventures III Abingworth Bioventures IIa Abingworth Bioventures II Abingworth Bioventures Biotechnology Venture Fund
|6.||Bioventures Management (51%):|
Peter Feinstein, General Partner Mr. Feinstein co-founded BioVentures Investors with Marc Goldberg and has been a General Partner since the inception of Fund I in 1999. In 1987, he founded Feinstein Kean Healthcare in Cambridge, MA, providing consulting and communications services to the biotechnol...
|7.||Abingworth - Portfolio Companies (48%):|
Portfolio Companies Biotechnology Venture Fund Alkermes (Cambridge, Mass.) is focused on developing proprietary systems to enable drugs across the blood-brain barrier, for the oral delivery of proteins and for sustained release and pulmonary drug delivery. Alkermes went public in July 1991. (08/87) ...
*** Replace left1.gif through left7.gif with the appropriate left-side image components e.Lilly Venture Fund Portfolio | Lilly BioVenture Fund Portfolio | Lilly MedTech Venture Fund Portfolio Bayhill Therapeutics , Palo Alto, CA. Bayhill Therapeutics is focused on the translation of research into t...
|9.||BioAdvance Ventures : News : Press Releases : September 23, 2004 (45%):|
News BioAdvance Ventures Announces Closing of $26 Million Early Stage Life Sciences Fund BioAdvance and Quaker BioVentures Partner to Attract More National Life Sciences Investment to Philadelphia Region Philadelphia and Wayne, PA - September 23, 2004 - BioAdvance, the Biotechnology Greenhouse of So...
|10.||Abingworth - Portfolio Companies (45%):|
Portfolio Companies Abingworth Bioventures 3-Dimensional Pharmaceuticals (Yardley, Pennsylvania) is a drug discovery company integrating structure-based drug design, combinatorial chemistry, computational software and chemi-informatics. The company went public in August 2000 and was acquired by John...
|11.||Drug Delivery Technologies: BD (44%):|
BD Worldwide Privacy Terms & Conditions Site Map Advanced Search BD - Worldwide Select a BD Location BD Technologies About BD Technologies Focus Areas BioVenture Center Business Development Contact Us Calendar of Events The BD Vacutainer® blood collection system traces its history back to 19...
|12.||Drug Delivery Technologies: BD (44%):|
BD Worldwide Privacy Terms & Conditions Site Map Advanced Search BD - Worldwide Select a BD Location BD Technologies About BD Technologies Focus Areas BioVenture Center Business Development Contact Us Calendar of Events BD manufactured the first syringe made specifically for insulin injection. L...
|13.||Abingworth - News (43%):|
News Abingworth raises $225 million fund London, UK, 5 December 2001 - Abingworth Management, the life sciences venture capital group, today announced a final closing of $225 million for Abingworth Bioventures III LP (ABVIII), its new life science venture fund. The fund was oversubscribed and was ca...
|14.||BIOVENTURES INVESTORS - BACKGROUND (43%):|
W e believe that investing in private equity provides a means of participating in the dynamic commercial development of new life-science technology with a degree of insulation from the public markets. Surging interest in genomics and basic medical research is feeding a remarkable expansion of our u...
|15.||BioAdvance, The Biotechnology Greenhouse of Southeastern Pennsylvania (40%):|
BioAdvance Ventures is an innovative new venture fund formed to invest in seed and early stage life science companies, located primarily in Southeastern Pennsylvania. The fund is sponsored by BioAdvance, and will be managed by Quaker BioVentures Inc., ( www.quakerbio.com ). The Fund s goal is to pr...
|16.||BioAdvance Ventures : Team (39%):|
Ira M. Lubert | Brenda D. Gavin | P. Sherrill Neff | Richard Kollender | Matthew Rieke, M.D. | Peter Sears | Geeta Vemuri, Ph.D. Patrick Lee Our Team Geeta Vemuri, Ph.D. Senior Associate Dr. Vemuri joined Quaker BioVentures as a Senior Associate in 2003. She brings years of experience in biomedical ...
|17.||Abingworth - News (36%):|
News New anti-infectives company - Novexel - spun-out of the Sanofi-Aventis Group with 40M funding from Atlas-led VC group Paris, France, 03 December 2004 Read full article (external site) Inpharmatica successfully closes GBP13.9M (USD25M) third round financing London, UK, 08 November 2004 Read full...
|18.||BioAdvance Ventures : About Us (36%):|
About Us BioAdvance Ventures is an innovative new venture fund formed to invest in seed and early stage life science companies, located primarily in Southeastern Pennsylvania. The fund is sponsored by BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania and is managed by...
|19.||Flagship Ventures (35%):|
Flagship & Portfolio Company News Archives 2003 2002 GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS Cambridge, MA, March 1, 2005 GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has changed it...
|20.||BioAdvance Ventures : News : Press Releases : December 13, 2004 (35%):|
News Neotropix Attracts $10 Million Series A Round For Development of Novel Virotherapies to Treat Cancer MALVERN, Pa.--(BUSINESS WIRE)--Dec. 13, 2004-- VIMAC Milestone Medica, Quaker BioVentures, and The Aurora Funds Co-lead Investment in Pennsylvania-based Company Neotropix(TM), Inc., a company de...